September 27th 2024
Kathleen A. Dorritie, MD, discusses acalabrutinib with or without obinutuzumab vs obinutuzumab plus chlorambucil in treatment-naïve CLL.
July 3rd 2024
Kathleen A. Dorritie, MD, discusses unmet needs regarding upfront treatment selection in chronic lymphocytic leukemia.
May 24th 2024
Kathleen A. Dorritie, MD, discusses the significance of results from the phase 3 NCRI-FLAIR study in previously untreated chronic lymphocytic leukemia.
November 24th 2020
Kathleen A. Dorritie, MD, discusses transplant eligibility in multiple myeloma.